Osteoporosis is not an absolute contraindication to dental implantation. Contemporary research indicates that implant survival in patients with osteoporosis exceeds 90% and is comparable to that of healthy individuals - provided correct qualification and an appropriate treatment protocol.
In Poland, osteoporosis affects around 2.1 million people, mainly post-menopausal women. Many of these patients need prosthetic restorations, and dental implants are the gold standard for reconstructing missing teeth. However, does weakened bone density preclude this method? In this article, we present the current state of knowledge based on systematic reviews and meta-analyses, and explain what to look out for before surgery.
What is osteoporosis and how does it affect jawbones?
Osteoporosis is a generalised skeletal disease characterised by reduced bone mass and degradation of the microarchitecture of bone tissue, leading to increased bone fragility. According to the World Health Organisation (WHO), osteoporosis is diagnosed when bone mineral density (BMD) measured by DEXA is at least 2.5 standard deviations below the peak value in young healthy individuals (T-score ≤ -2.5). Osteopenia, the initial phase of bone weakness, corresponds to a T-score between -1.0 and -2.5.
Although osteoporosis primarily affects the spine, hip and wrist, it also involves the jawbone. Reduced alveolar bone density can theoretically impede the process of osteointegration - that is, the ingrowth of the implant into the bone. However, the key clinical question is: does this mechanism actually translate into implant survival?
What do the scientific studies say? Survival of implants in patients with osteoporosis
Recent reviews of studies clearly indicate that osteoporosis alone is not an absolute contraindication to implantation. Implant survival in patients with reduced bone density remains high and is not statistically significantly different from the results in the control group.
A meta-analysis by Lemos et al (2023) involving studies with 1132 patients and 3505 implants showed no significant difference in implant survival between patients with osteoporosis and healthy subjects. However, the authors emphasise that significantly greater marginal bone loss around the implants was observed in patients with osteoporosis.
The meta-analysis by Kim et al (2025), published in the Journal of Clinical Medicine, summarises comparative studies from 2014-2024 and confirms that osteoporosis per se does not interfere with implantation outcomes - survival rates were not significantly different between groups.
In contrast, a review by de Madeiros et al (2018), involving 8859 patients and 29,798 implants, confirmed these findings at both implant and patient level. At the same time, there was a small but statistically significant increase in marginal bone loss in patients with osteoporosis.
Comparison of implantation outcomes: patients with osteoporosis vs healthy subjects
| Parameter | Osteoporosis | Healthy patients | Significant difference? |
| Survival of implants | > 90% | > 90% | NO |
| Marginal bone loss (MBL) | Slightly higher | Reference value | YES |
| Osteointegration | Correct (with correct protocol) | Correct | NO |
| Healing time | Can be extended (3-6 months) | Standard (3-6 months) | Individually |
Bisphosphonates and dental implants - key risks: MRONJ
More challenging than osteoporosis itself is the use of antiresorptive drugs - bisphosphonates (e.g. alendronate, ryzedronate, zoledronic acid) and denosumab. These drugs inhibit bone resorption, which is desirable in the treatment of osteoporosis, but at the same time slow down bone remodelling in the maxilla and mandible, raising the risk of medication-related osteonecrosis of the jaw (MRONJ).
MRONJ is a rare but serious complication in which a fragment of the jawbone stops healing properly and may become exposed in the oral cavity. It affects patients on long-term osteoporosis medication (bisphosphonates, denosumab).
MRONJ risk - figures
- Pacjenci leczeni doustnymi bisfosfonianami z powodu osteoporozy: ryzyko MRONJ szacowane na 0,01–0,10% (1 na 1000–10 000 pacjentów).
- Patients treated with intravenous bisphosphonates for cancer: risk of MRONJ increases to 1-10%.
- Pooled percentage of post-implantation MRONJ in people taking antiresorptive drugs for osteoporosis: approximately 0.5% (according to a 2025 systematic review and meta-analysis including 21 cohorts).
- Czynniki zwiększające ryzyko MRONJ: terapia bisfosfonianami > 3 lata, jednoczesne stosowanie kortykosteroidów, implantacja w odcinku bocznym żuchwy.
The AAOMS position statement (update 2022) recommends that when implanting in patients on antiresorptive treatment for osteoporosis, informed consent should be obtained from the patient including information about the low risk of MRONJ and the possibility of early and late implant loss.
Step-by-step qualification of a patient with osteoporosis for implantation
The decision to implant in a person with osteoporosis should be based on a comprehensive assessment of the condition and not on the diagnosis of osteoporosis alone. Below are the key stages of qualification:
- Medical and pharmacological history - type, dose and duration of antiresorptive therapy; use of corticosteroids; DEXA test result (T-score); comorbidities (diabetes, autoimmune diseases).
- CBCT imaging diagnostics - 3D cone tomography allows precise assessment of the alveolar bone density, the volume of available bone and planning of the optimal implant position.
- Oral assessment - treatment of caries, periodontal disease and elimination of inflammatory foci BEFORE implantation.
- Individual treatment plan - choice of implant system, consideration of bone augmentation (if bone volume is insufficient), determination of extended osteointegration time.
Is osteoporosis a contraindication to implantation?
No - osteoporosis is not an absolute contraindication to dental implantation. According to the current state of knowledge, this disease only requires special caution and a modified clinical protocol. Absolute contraindications rather apply to patients treated with intravenous bisphosphonates in oncological doses (e.g. for cancer metastases to bone).
For osteoporosis treated orally (e.g. with alendronate or risedronate), implantation is considered to be a safe procedure as long as the conditions for proper qualification are met. The most recent systematic review (2025), including 24 studies and 5954 implants in 2102 patients, confirms survival rates above 90% even in the osteoporosis group.
How to increase the chances of implant success in osteoporosis?
By modifying the implant protocol, the risk of complications can be minimised and optimal osteointegration can be ensured even with reduced bone density. Below are the strategies used by professionals:
- Extended osteointegration time - Instead of the standard 3-4 months, in patients with osteoporosis the doctor may recommend 5-6 months before prosthetic loading.
- An implant with a suitable surface - systems with a micro-textured, hydrophilic surface promote faster osteointegration in bone with reduced density.
- Bone augmentation - In case of bone volume deficiency, bone reconstruction (e.g. sinus lift, GBR) is used before or at the same time as implantation.
- Vitamin D and calcium supplementation - compensating for deficiencies supports bone metabolism and healing.
- Oral hygiene - Patients with osteoporosis should take special care with hygiene to minimise inflammation around the implant (periimplantitis).
- Regular follow-up visits - monitoring the condition of the implant and marginal bone every 6 months.
Frequently Asked Questions (FAQ)
Can I have dental implants with osteoporosis?
Yes - osteoporosis is not an absolute contraindication to implantation. Contemporary studies involving thousands of patients show implant survival rates above 90% also in people with reduced bone density. Individual qualification and an appropriate treatment protocol are key. Make an appointment for a consultation at Modern Dental & Orthodontics (MDO Clinic).
Will the implant accept with weak bone?
Meta-analyses confirm that osteointegration (ingrowth of the implant into the bone) usually goes well in patients with osteoporosis. Bone-implant contact is comparable to results in healthy individuals. The doctor can extend the healing period and use an implant with a special surface that promotes faster ingrowth.
How long does it take to heal after an implant in a person with osteoporosis?
The healing time depends on many factors and is determined on an individual basis. Normally, osteointegration takes 3-6 months. In patients with osteoporosis, the implantologist may extend this period by 1-2 months to ensure that the implant fully grows into the bone before being loaded with a prosthetic crown.
Is osteopenia also a problem with implants?
Osteopenia (incipient bone weakness) represents a lower risk than advanced osteoporosis. Studies indicate that implant survival rates in patients with osteopenia are similar to those in healthy patients. Nevertheless, it is worth informing the implantologist of the diagnosis - this will allow the optimal choice of treatment protocol.
Read more on Modern Dental & Orthodontics
▶ Dental implants Warsaw Wola | Implant placement
▶ Does inserting implants hurt?
▶ Implant or bridge - which is better?
▶ How much does an implant with a crown cost?
▶ What to avoid with dental implants?
Sources
[1] https://pubmed.ncbi.nlm.nih.gov/37043030/
Lemos CAA, de Oliveira AS, Faé DS, et al. „Do dental implants placed in patients with osteoporosis have higher risks of failure and marginal bone loss compared to those in healthy patients? A systematic review with meta-analysis.” Clin Oral Investig. 2023;27(6):2483–2493.
[2] https://www.mdpi.com/2077-0383/14/19/6719
Kim SY, Lee YJ, Kang YJ, Kim SG, Rotaru H. „Impact of Osteoporosis on Dental Implant Survival, Failure, and Marginal Bone Loss: A Systematic Review and Meta-Analysis”. J Clin Med. 2025;14(19):6719. doi: 10.3390/jcm14196719.
[3] https://pubmed.ncbi.nlm.nih.gov/28651805/
de Medeiros FCFL, Kudo GAH, Leme BG, Saraiva PP, Verri FR, Honório HM, Pellizzer EP, Santiago Junior JF. „Dental implants in patients with osteoporosis: a systematic review with meta-analysis”. Int J Oral Maxillofac Surg. 2018;47(4):480-491. doi: 10.1016/j.ijom.2017.05.021.
[4] https://pubmed.ncbi.nlm.nih.gov/39804249/
Shibli JA, Naddeo V, Cotrim KC, Kalil EC, Dorigatti de Avila E, Faot F, Faverani LP, Souza JGS, Fernandes JCH, Fernandes GVO. „Osteoporosis’ effects on dental implants osseointegration and survival rate: a systematic review of clinical studies”. Quintessence Int. 2025;56(3):206-216. doi: 10.3290/j.qi.b5927487.
[5] https://doi.org/10.1016/j.joms.2022.02.008
Ruggiero SL, Dodson TB, Aghaloo T, et al. „American Association of Oral and Maxillofacial Surgeons’ Position Paper on Medication-Related Osteonecrosis of the Jaws - 2022 Update.” J Oral Maxillofac Surg. 2022;80(5):920-943.
[6] https://pubmed.ncbi.nlm.nih.gov/40505730/
Mirza R, El Rabbany M, Ali DS, Tetradis S, Morrison A, Ruggiero S, Alnajimi R, Khan AA, Guyatt G. „Dental Implant Failure and Medication-Related Osteonecrosis of the Jaw Related to Dental Implants in Patients Taking Antiresorptive Therapy for Osteoporosis: A Systematic Review and Meta-Analysis”. Endocr Pract. 2025;31(9):1189-1196. doi: 10.1016/j.eprac.2025.06.003.
Information on content and responsibility
This article is intended solely for informational and educational purposes and does not constitute medical advice, a diagnosis or a treatment recommendation. It does not replace a consultation with a dentist or other qualified specialist. Despite every effort to ensure accuracy, the authors accept no liability for decisions made by readers on the basis of the information contained herein.